These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23483575)

  • 21. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of corticosteroids in muscular dystrophy: a critical appraisal.
    Angelini C
    Muscle Nerve; 2007 Oct; 36(4):424-35. PubMed ID: 17541998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review.
    Ryder S; Leadley RM; Armstrong N; Westwood M; de Kock S; Butt T; Jain M; Kleijnen J
    Orphanet J Rare Dis; 2017 Apr; 12(1):79. PubMed ID: 28446219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
    Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
    J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
    Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
    J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacotherapy of Duchenne Muscular Dystrophy.
    Hoffman EP
    Handb Exp Pharmacol; 2020; 261():25-37. PubMed ID: 31375923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
    Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
    Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
    Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
    J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey.
    McMillan HJ; Campbell C; Mah JK;
    Can J Neurol Sci; 2010 Mar; 37(2):195-205. PubMed ID: 20437929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
    Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
    Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duchenne muscular dystrophy: an historical treatment review.
    Werneck LC; Lorenzoni PJ; Ducci RD; Fustes OH; Kay CSK; Scola RH
    Arq Neuropsiquiatr; 2019 Sep; 77(8):579-589. PubMed ID: 31508685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.
    Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ;
    Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet.
    Butterfield RJ; Kirkov S; Conway KM; Johnson N; Matthews D; Phan H; Cai B; Paramsothy P; Thomas S; Feldkamp ML
    Muscle Nerve; 2022 Jul; 66(1):15-23. PubMed ID: 34994466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations.
    Sejerson T; Bushby K;
    Adv Exp Med Biol; 2009; 652():13-21. PubMed ID: 20225016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
    Kourakis S; Timpani CA; Campelj DG; Hafner P; Gueven N; Fischer D; Rybalka E
    Orphanet J Rare Dis; 2021 Mar; 16(1):117. PubMed ID: 33663533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.